{
    "clinical_study": {
        "@rank": "92553", 
        "acronym": "ANRS ECHAM", 
        "brief_summary": {
            "textblock": "This study will allow to assess liver related injuries in HIV patients."
        }, 
        "brief_title": "Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "HIV Infection", 
            "Liver Injuries"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a cross-sectional, multicentre study including 8 centres from 3 European\n      countries (Belgium, France, Germany).\n\n      The maximum duration of the study for each patient will be 4 months, consisting of:\n\n        -  a screening visit,\n\n        -  an inclusion visit to perform the biologic tests and exams necessary for the study,\n           within 1 month after the screening visit,\n\n        -  a result delivery visit within 1 month after inclusion visit, to disclose results of\n           previous investigations. Patients with one or two non invasive markers suggesting\n           significant fibrosis (\u2265F2) will be invited for liver biopsy within the next 2 months.\n\n        -  a \"liver biopsy\" visit, within 2 months after visit 2, liver biopsy in selected and\n           consented patients"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u226540 years\n\n          2. Infection with HIV-1\n\n          3. Cumulative exposure to cART for at least 5 years and currently under cART\n\n          4. Viral load < 400 copies/mL\n\n          5. CD4 count > 100 CD4/mm3\n\n          6. Female may be eligible to enter and participate in the study if she:\n\n               -  is of non-child-bearing potential defined as either post-menopausal (12 months\n                  of spontaneous amenorrhea and \u226545 years of age) or physically incapable of\n                  becoming pregnant with documented tubal ligation, hysterectomy or bilateral\n                  oophorectomy or\n\n               -  is of child-bearing potential with a negative blood pregnancy test at screening\n                  visit\n\n          7. Informed consent signed prior to any study procedure\n\n          8. To be covered by a medical insurance (only for French centres)\n\n          9. Presence of:\n\n               -  the metabolic syndrome as defined by the most recent international consensus\n                  definition (Alberti et al. Circulation 2009) including three components among\n                  the following criteria:\n\n                    -  visceral obesity (waist circumference: Europeans and Africans \u2265 94 cm for\n                       men and \u2265 80 cm for women, Americans \u2265 102 cm for men and \u2265 88 cm for\n                       women, Asians \u2265 90 cm for men and \u2265 80 cm for women)\n\n                    -  blood glucose \u2265 1 g/L (5,6 mmol/L) or anti-diabetic treatment,\n\n                    -  serum triglycerides \u2265 1,5 g/L (1,7 mmol/L) or hypertriglycerides treatment,\n\n                    -  serum HDL cholesterol < 0,4 g/L (1 mmol/L) for men and < 0,5 g/L (1,3\n                       mmol/L) for women or hypercholesterolemia treatment,\n\n                    -  blood pressure (Diastolic \u2265130 mmHg and/or Systolic \u2265 85 mmHg) or\n                       antihypertensive treatment\n\n               -  and/or clinical lipoatrophy and/or lipohypertrophy using clinical questionnaires\n                  used and validated in previous published studies (ANRS 121 Hippocampe trial),\n\n               -  and/or chronic elevated transaminases \u2265 1.5 ULN and / or GGT \u2265 2 ULN confirmed\n                  by two blood samples within at least three-month interval over twelve months\n                  prior screening visit.\n\n        Exclusion Criteria:\n\n          1. Coinfection with hepatitis B (positive HBs antigen or isolated positive HBc antibody\n             with positive PCR)\n\n          2. Positive HCV serology\n\n          3. Coinfection HIV-1 and HIV-2\n\n          4. Use of intravenous drugs within the last six months\n\n          5. Excessive alcohol intake (male > 50 g/d, female > 40 g/d)\n\n          6. Other causes of liver diseases i.e: viral hepatitis, hemochromatosis, Wilson disease,\n             autoimmune hepatitis, primary or secondary biliary cirrhosis, primary or secondary\n             cholangitis, \u03b11 antitrypsine deficiency\n\n          7. Other causes of liver steatosis: current steroid therapy, current therapy with\n             amiodarone, tamoxifen, methotrexate, nifedipine, or hycanthone; history of cancer\n             chemotherapy; short bowel syndrome, polycystic ovarian syndrome, Weber-Christian\n             disease\n\n          8. Active opportunistic infection except for candida oesophagitis\n\n          9. Current Cancer\n\n         10. Pregnancy\n\n         11. Decompensated heart failure\n\n         12. Subject under legal guardianship\n\n         13. Inability to give informed consent or incapacitation\n\n         14. Contra-indication to MRI: pace-maker, neurovascular surgery, intraocular materials,\n             cochlear implant, severe claustrophobia\n\n         15. Participation in another study with an ongoing exclusion period at screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "560", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02093754", 
            "org_study_id": "ECHAM", 
            "secondary_id": "2012-A01670-43"
        }, 
        "intervention": {
            "intervention_name": "MRI and biopsy", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }
                }, 
                "investigator": {
                    "last_name": "St\u00e9phane De Wit, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }
                }, 
                "investigator": [
                    {
                        "last_name": "Jean-Luc Meynard, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Christine Katlama, Pr", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }
                }, 
                "investigator": [
                    {
                        "last_name": "Georg Behrens, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jan Van Lunzen, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Patrick Ingiliz, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Stefan Mauss, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients: a European Multicentre Study", 
        "overall_contact": {
            "email": "m.lemoine@imperial.ac.uk", 
            "last_name": "MAUD LEMOINE, MD"
        }, 
        "overall_official": {
            "affiliation": "Medical Research Council", 
            "last_name": "Maud LEMOINE, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of steatosis detected by MRI", 
            "safety_issue": "No", 
            "time_frame": "Within 6 months after all patients have completed MRI"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02093754"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of fibrosis or cirrhosis using non invasive markers and concordance of non invasive markers", 
                "safety_issue": "No", 
                "time_frame": "Within 6 months after all patients have completed the study"
            }, 
            {
                "measure": "Risk factors (age, duration of infection, treatment, clinical and biological metabolic and adipose tissue parameters) of liver injuries", 
                "safety_issue": "No", 
                "time_frame": "Within 6 months after all patients have completed the study"
            }, 
            {
                "measure": "Independent risk factors of NAFLD, NASH and fibrosis (including markers of insulin resistance, inflammatory cytokines, markers of immune activation, adipokines)", 
                "safety_issue": "No", 
                "time_frame": "Within 6 months after all patients have completed the study"
            }, 
            {
                "description": "Quantifiable levels of serum adiponectin, serum leptin, serum HS-IL-6, HS-CRP, serum s-CD14 will be measured.", 
                "measure": "Establish a diagnosis score based on biomarkers of liver injuries (Adiponectin, leptin, IL6, CRP, CD14)", 
                "safety_issue": "No", 
                "time_frame": "Within 6 months after all patients have completed the study"
            }, 
            {
                "description": "Autophagosome formation in the liver biopsis (only for patients presenting liver fibrosis equal or > 2 will be quantified.", 
                "measure": "Description of pathogenetic factors and correlates with autophagy in liver biopsies of patients with evidence for liver fibrosis", 
                "safety_issue": "No", 
                "time_frame": "Within 6 months after all patients have completed the study"
            }, 
            {
                "description": "Quantifiable levels of T cell activation (in PBMC), Frequency and phenotype of Tregs (in PBMC), Quantifiable levels of NK cells (in PBMC), Quantifiable levels of Th17 and \u03b3\u03b4 T cell (in PBMC), Quantifiable levels of Plasma LPS and LPB (sCD163, CD26, Cytokeratin 18) will be measured.", 
                "measure": "Identification of features of the adaptive immune system associated to NAFLD, NASH and fibrosis (T cell activation, surface expression of Treg, NK cells, NKT cells)", 
                "safety_issue": "No", 
                "time_frame": "Within 6 months after all patients have completed the study"
            }, 
            {
                "measure": "Impact of IL28B and PNPLA3 genetic polymorphisms on the severity of liver steatosis, inflammation and fibrosis", 
                "safety_issue": "No", 
                "time_frame": "Within 6 months after all patients have completed the study"
            }, 
            {
                "measure": "Percentage of patients with NASH, fibrosis and cirrhosis on liver biopsy", 
                "safety_issue": "No", 
                "time_frame": "Within 6 months after all patients have completed the study"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}